With this launch, the company intends to revolutionize Obstructive Airway Disease (OAD) diagnosis, in line with its ambition to strengthen its position as the lung leader in India.
This is a part of the Company’s ‘LungAttack’ campaign that endeavors to drive awareness about COPD and encourage early diagnosis.
Cipla said Spirofy is a result of 5 years of meticulous in-house research by the Integrated Product Development (IPD) team, and it aims to transform Obstructive Airway Disease (OAD) diagnosis in India.
“The device ensures high result accuracy and individual patient safety using Bacterial Viral Filters,” the company added.
Cipla added that Spirofy is a wireless device with good battery backup, making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians’ flexibility and ease of use.
“The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a pdf version can be shared on the phone. Cipla will undertake training of physicians in the interpretation of spirometry results,” the company said.
Spirometry is the gold standard for COPD diagnosis, however owing to the bulky size, complex functionality, need for regular maintenance are some reasons that impacted the widespread acceptance of conventional spirometers by medical practitioners.
This resulted in underdiagnosis or misdiagnosis of COPD cases in India. Currently, COPD remains the second most common cause of death in India after heart diseases, where India alone bears 32% of the global COPD burden.